Cost-effectiveness studies in ovarian cancer

Area of Science:

• Oncology
• Health Economics

Background:

• Ovarian cancer is a leading cause of cancer deaths, imposing significant costs on individuals and healthcare systems.
• Current ovarian cancer screening strategies lack proven efficacy in improving patient outcomes.
• Ongoing randomized controlled trials are evaluating the impact of ultrasound and CA125 screening on mortality.

Purpose of the Study:

• To review and discuss available cost-effectiveness and cost-utility studies of ovarian cancer treatments.
• To compare the cost-effectiveness of standard chemotherapy regimens, such as paclitaxel and carboplatin, with other options.
• To highlight the importance of considering patient quality of life in clinical treatment decisions.

Main Methods:

• Review of existing cost-effectiveness and cost-utility analyses of ovarian cancer therapies.
• Analysis of studies comparing different chemotherapy regimens, including paclitaxel and cisplatin.
• Consideration of direct medical costs, supportive care costs, and patient-reported outcomes.

Main Results:

• Incremental costs of new therapies, including chemotherapy drugs, often fall within acceptable ranges.
• While novel drugs may have higher acquisition costs, they can lead to overall cost savings through reduced supportive and palliative care expenses.
• Quantifying patient costs like pain and suffering remains challenging but is vital for decision-making.

Conclusions:

• Cost-effectiveness analyses are essential for evaluating ovarian cancer treatments.
• The financial impact of chemotherapy, including newer agents, needs careful assessment alongside patient quality of life.
• Informed clinical decisions require a comprehensive understanding of both economic and patient-centered factors.